Rossari Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rossari Biotech Limited's yearly results (2023–2026), compared with Basic Materials companies in India. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 94% of Basic Materials companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹83 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 93% of Basic Materials companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 93% of Basic Materials companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹59Over the last 3 years, every ₹100 of reported profit came with ₹59 of operating cash.
Lower than 78% of Basic Materials companies in India.
Self-Funding Ratio
0.4×Over the last 3 years its own operating cash paid for 44% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 77% of Basic Materials companies in India.
Cash Locked Ratio
₹26For every ₹100 of sales, ₹26 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹21 tied up three years earlier.
More money tied up than 63% of Basic Materials companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 94% of Basic Materials companies in India.
Growth Efficiency Ratio
₹6Sales grew 45% in 3 years; of every extra ₹100 of sales, ₹6 became extra profit.
Lower than 57% of Basic Materials companies in India.
Asset Productivity Ratio
+45% / +67%In 3 years sales changed by +45% while total assets changed by +67%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 71% of Basic Materials companies in India.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 59% of Basic Materials companies in India.
Tangible Assets Ratio
90%Of every ₹100 the company owns, ₹90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 93% of Basic Materials companies in India.
Tangible Net Worth Ratio
83%Of every ₹100 of net worth, ₹83 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 93% of Basic Materials companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Rossari Biotech Limited owes ₹0.42 for every ₹1 it owns. Net profit rose 9% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Compared with Basic Materials companies in India · latest annual results Mar 2026.
P/E ratio
15.7Investors pay ₹15.7 for every ₹1 of Rossari Biotech Limited's yearly profit, lower than 64% of Basic Materials companies in India.
P/B ratio
1.78The share price is 1.78 times Rossari Biotech Limited's book value per share, lower than 53% of Basic Materials companies in India.
Market cap
₹2,367 CrThe total market value of all of Rossari Biotech Limited's shares at today's price (share price × number of shares), larger than 55% of Basic Materials companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,333 CrWhat Rossari Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹240.70Net worth divided by the number of shares. The share price of ₹427.30 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
11.3%Rossari Biotech Limited earned 11.3% on its shareholders' money over the last year, higher than 55% of Basic Materials companies in India.
Owes vs Owns
0.42×Rossari Biotech Limited owes ₹0.42 for every ₹1 it owns (low), higher than 56% of Basic Materials companies in India.
Dividend yield
0.12%Rossari Biotech Limited pays 0.12% of its share price as dividends a year, lower than 91% of dividend-paying Basic Materials companies in India.
Revenue growth
+15%Revenue rose 15% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+9%Net profit rose 9% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Profit margin
6.2%Rossari Biotech Limited keeps ₹6 of every ₹100 of revenue as net profit.
Cash quality
0.4×Cash from Rossari Biotech Limited's business was 0.4× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
6.7×Rossari Biotech Limited's operating profit covered its interest costs 6.7 times in the year to Mar 2026.
Cash vs debt
Net debtRossari Biotech Limited had ₹323 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Rossari Biotech Limited's P/E ratio?
Investors pay ₹15.7 for every ₹1 of Rossari Biotech Limited's yearly profit, lower than 64% of Basic Materials companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rossari Biotech Limited: ₹2,367 Cr ÷ ₹1,333 Cr (31 Mar 2026) = 1.8.
What is Rossari Biotech Limited's return on equity?
Rossari Biotech Limited earned 11.3% on its shareholders' money over the last year, higher than 55% of Basic Materials companies in India.
How much does Rossari Biotech Limited owe compared with what it owns?
Rossari Biotech Limited owes ₹0.42 for every ₹1 it owns (low), higher than 56% of Basic Materials companies in India.
Does Rossari Biotech Limited pay a dividend?
Yes. Rossari Biotech Limited pays 0.12% of its share price as dividends a year, lower than 91% of dividend-paying Basic Materials companies in India.
Is Rossari Biotech Limited's revenue growing?
Revenue rose 15% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.